A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma-Reference-Cited by-同舟云学术

A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma

Published:2017-02-13 Issue:11 Volume:123 Page:1979-1988
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Goyal Lipika¹²,Zheng Hui³,Yurgelun Matthew B.²⁴,Abrams Thomas A.²⁴,Allen Jill N.¹²,Cleary James M.²⁴,Knowles Michelle¹,Regan Eileen⁴,Reardon Amanda¹,Khachatryan Anna⁵,Jain Rakesh K.²⁵,Nardi Valentina²⁶,Borger Darrell R.²⁶,Duda Dan G.²⁵,Zhu Andrew X.¹²

Affiliation:

1. Department of Medicine; Massachusetts General Hospital Cancer Center; Boston Massachusetts

2. Harvard Medical School; Boston Massachusetts

3. Biostatistics Center; Massachusetts General Hospital; Boston Massachusetts

4. Dana-Farber Cancer Institute; Boston Massachusetts

5. Department of Radiation Oncology; Massachusetts General Hospital; Boston Massachusetts

6. Department of Pathology; Massachusetts General Hospital; Boston Massachusetts

Funder

ClinicalTrials.gov

National Institutes of Health

Exelixis

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections;Nagino;Ann Surg.,2013

2. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med.,2010

3. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study;Walter;Eur J Cancer.,2013

4. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma;Yoshikawa;Br J Cancer.,2008

5. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas;Hida;Anticancer Res.,1999

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Therapies in Management of Cholangiocarcinoma;Cancers;2024-01-31

2. MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature;Therapeutic Advances in Medical Oncology;2024-01

3. Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma;Frontiers in Oncology;2023-12-07

4. Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review;Frontiers in Oncology;2023-11-02

5. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma;Cancer Research;2023-09-27